BRPI0514976A - composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto - Google Patents

composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0514976A
BRPI0514976A BRPI0514976-2A BRPI0514976A BRPI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
substituted
pharmaceutical composition
15beta
Prior art date
Application number
BRPI0514976-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Hubert Jan Jozef Loozen
Antonius Gerardus Hen Ederveen
Fredericus Antonius Dijcks
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of BRPI0514976A publication Critical patent/BRPI0514976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0514976-2A 2004-09-08 2005-09-05 composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto BRPI0514976A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60850104P 2004-09-08 2004-09-08
EP04104334 2004-09-08
PCT/EP2005/054368 WO2006027347A1 (en) 2004-09-08 2005-09-05 15β-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY

Publications (1)

Publication Number Publication Date
BRPI0514976A true BRPI0514976A (pt) 2008-07-01

Family

ID=34929554

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514976-2A BRPI0514976A (pt) 2004-09-08 2005-09-05 composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto

Country Status (20)

Country Link
US (1) US7838516B2 (enExample)
EP (1) EP1805201B1 (enExample)
JP (1) JP4889644B2 (enExample)
AR (1) AR050732A1 (enExample)
AT (1) ATE414710T1 (enExample)
AU (1) AU2005281705B2 (enExample)
BR (1) BRPI0514976A (enExample)
CA (1) CA2577497C (enExample)
DK (1) DK1805201T3 (enExample)
ES (1) ES2317312T3 (enExample)
NZ (1) NZ553266A (enExample)
PE (1) PE20060590A1 (enExample)
PL (1) PL1805201T3 (enExample)
PT (1) PT1805201E (enExample)
RS (1) RS51640B (enExample)
RU (1) RU2386637C2 (enExample)
SI (1) SI1805201T1 (enExample)
TW (1) TW200621795A (enExample)
UA (1) UA89964C2 (enExample)
WO (1) WO2006027347A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
WO2011000540A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing 3,3,5,5-tetramethylcyclohexanone
US20120116125A1 (en) * 2009-06-29 2012-05-10 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
PL2448910T3 (pl) * 2009-06-29 2013-10-31 Merz Pharma Gmbh & Co Kgaa Sposób wytwarzania nerameksanu
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SI2764008T1 (sl) * 2011-10-07 2016-10-28 Estetra S.P.R.L. Postopek za pripravo estetrola
CN105518015B (zh) 2013-06-25 2017-09-15 佛恩多制药有限公司 治疗活性的作为17β‑羟基类固醇脱氢酶抑制剂的17‑氮取代雌三烯噻唑衍生物
EP3013845B1 (en) 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
US9850272B2 (en) 2013-06-25 2017-12-26 Forendo Pharma Ltd. Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta-hydroxy-steroid dehydrogenase, type 1
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
WO2016102776A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd Prodrugs of 17.beta.-hsd1 -inhibitors
KR102662025B1 (ko) 2015-06-18 2024-05-02 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 에스테트롤 성분을 함유하는 구강분해성 투여 단위
HUE054551T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Ösztetrolt tartalmazó, szájban diszpergálódó tabletta
NZ737948A (en) 2015-06-18 2023-03-31 Estetra Sprl Orodispersible dosage unit containing an estetrol component
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
NZ760155A (en) 2017-06-08 2022-09-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
KR20210114390A (ko) 2018-12-05 2021-09-23 포렌도 파마 리미티드 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL226738A (enExample) 1957-04-11
DE1084261B (de) 1957-04-11 1960-06-30 Syntex Sa Verfahren zur Herstellung neuer Cyclopentanophenanthrenderivate
US3257429A (en) * 1957-11-12 1966-06-21 Syntex Corp 16-methylene derivatives of estrone and estradiol
US3007946A (en) 1958-11-06 1961-11-07 Searle & Co 3-alkoxy-16-methylene-1, 3, 5(10)-estratrien-17-ones
US3049555A (en) 1959-12-22 1962-08-14 Searle & Co 3-alkoxy-16-methyl-1, 3, 5 (10)-estratrien-17-ones
US3092645A (en) 1961-12-28 1963-06-04 Searle & Co Esters of 17alpha-alkynylester-5(10)-ene-3beta, 17beta-diols
GB1110792A (en) 1964-04-07 1968-04-24 Res Inst Medicine Chem Novel 5(10)-dehydro-steroids
US3299108A (en) 1965-10-18 1967-01-17 Searle & Co 17alpha-alkynyl/alkenyl-13beta-alkyl-11-alkylgona-1, 3, 5 (10)-triene-3, 17beta-diols, ethers and esters thereof and intermediates thereto
US3465010A (en) 1966-11-22 1969-09-02 Searle & Co 17 - (unsaturated hydrocarbon - substituted) 11,13beta - dialkylgon -4 - ene - 3,17beta-diols and esters thereof
US3377366A (en) 1966-12-02 1968-04-09 Searle & Co 17alpha-alkynyl/alkenyl-11, 13beta-dialkylgon-5(10)-en-3-ones and esters thereof
US3642992A (en) * 1967-09-08 1972-02-15 Upjohn Co Organic compounds
ZA712312B (en) 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds
US3652606A (en) 1970-08-07 1972-03-28 Searle & Co 3-oxygenated 11beta-methylestr-4-en-17beta-ol and esters thereof
US3704253A (en) 1970-09-23 1972-11-28 American Home Prod 13 - polycarbonalkyl - 16 - methylgona-1,3,5(10)-trienes and 13-polycarbonalkyl-16-methylgon - 4 - en-3-ones and intermediates for their production
US3766224A (en) * 1971-06-03 1973-10-16 Sandoz Ag 15-methyl-substituted steroids
FR2377419A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
DE2757157C3 (de) 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
US5116830A (en) 1984-08-17 1992-05-26 Sri International Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
US5204337A (en) 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
ZA94715B (en) 1993-02-08 1994-10-24 Akzo Nv Steroids for treating menopausal complaints
AU671706B2 (en) 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
TW403736B (en) 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity
PL343428A1 (en) 1998-03-09 2001-08-13 Akzo Nobel Nv New contraceptive kit
CN1172949C (zh) 1998-06-19 2004-10-27 阿克佐诺贝尔公司 睾酮衍生物
ATE222922T1 (de) 1998-11-20 2002-09-15 Akzo Nobel Nv Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
JP2003508541A (ja) 1999-09-06 2003-03-04 アクゾ・ノベル・エヌ・ベー １１位に炭化水素置換基を有する非芳香族エストロゲンステロイド
JP2003513102A (ja) * 1999-11-02 2003-04-08 シエーリング アクチエンゲゼルシャフト 選択的な作用を有するエストロゲンとしての１８−ノル−ステロイド
HUP0301592A2 (hu) * 2000-07-28 2003-09-29 Akzo Nobel N.V. 16alfa-metil- vagy etil-szubsztituált ösztrogének és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
DK1805201T3 (da) 2009-01-12
CA2577497C (en) 2012-03-20
AR050732A1 (es) 2006-11-15
EP1805201B1 (en) 2008-11-19
US20070254860A1 (en) 2007-11-01
WO2006027347A1 (en) 2006-03-16
JP2008512426A (ja) 2008-04-24
PT1805201E (pt) 2008-12-31
ATE414710T1 (de) 2008-12-15
PE20060590A1 (es) 2006-07-14
RU2007112939A (ru) 2008-11-10
NZ553266A (en) 2009-06-26
AU2005281705B2 (en) 2011-03-10
US7838516B2 (en) 2010-11-23
RU2386637C2 (ru) 2010-04-20
TW200621795A (en) 2006-07-01
CA2577497A1 (en) 2006-03-16
EP1805201A1 (en) 2007-07-11
ES2317312T3 (es) 2009-04-16
RS20070075A (sr) 2008-09-29
PL1805201T3 (pl) 2009-04-30
AU2005281705A1 (en) 2006-03-16
UA89964C2 (ru) 2010-03-25
RS51640B (sr) 2011-10-31
SI1805201T1 (sl) 2009-04-30
JP4889644B2 (ja) 2012-03-07

Similar Documents

Publication Publication Date Title
BRPI0514976A (pt) composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BRPI0520812A2 (pt) método para preparar um composto de quinolina 4-substituìda, e, composto
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BRPI0517343A (pt) derivados de betulina, preparação destes e uso dos mesmos
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BR0308945A (pt) Derivados radiomarcados de quinolina e quinolinona e uso dos mesmos como ligantes para receptores de glutamato metabotrópicos
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
BR0312069A (pt) Compostos de benzimidazol e seu uso como agonistas/antagonistas de estrogênio
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BR0012697A (pt) Inibidores da diferenciação de th2
NO20062679L (no) Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
BRPI0417268A (pt) benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
BR0013009A (pt) Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos
BR0311410A (pt) Composto de piperidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2227 DE 10/09/2013.